Added to YB: 2024-03-18
Pitch date: 2024-03-18
AQST [bullish]
Aquestive Therapeutics, Inc.
-27%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Market Cap
$445.3M
Pitch Price
$5.42
Price Target
30.08 (+660%)
Dividend
N/A
EV/EBITDA
-6.70
P/E
-5.25
EV/Sales
8.24
Sector
Pharmaceuticals
Category
growth
Aquestive Therapeutics: Underappreciated Late-Stage Assets Present Significant Long-Term Opportunity Despite Recent Gains
AQST: $445M late-stage biotech. Anaphylm (sublingual epinephrine) superior to injectables & nasal; expands $1B+ market 50-60%. Libervant (sublingual diazepam) PDUFA 4/28. $24M cash, licensing deals soon. Upside: Anaphylm $700M+ by '28, 394% to '27 PT on fundamentals.
Read full article (14 min)